AbbVie Inc. (ABBV)
AbbVie's Growth Engine Is Firing On All Cylinders
AbbVie is a compelling 'Buy' as it has strong momentum in existing drugs and has a robust pipeline. Robust Q1 2026 results: net revenue up 12.4% YoY, driven by Immunology (Skyrizi +29%, Rinvoq +20%) and Neuroscience (+24%). Management raised 2026 EPS guidance to $14.18, signaling 42% YoY growth and confidence in ABBV's diversified growth drivers and pipeline.
AbbVie Deserves A Higher Multiple
AbbVie remains a buy as fundamentals strengthen and valuation sits near multiyear lows after recent stock underperformance. Q1 net revenues grew 12.4% YoY, indicating robust overall business activity despite some Immunology portfolio shakiness. Raised full-year 2026 EPS guidance signals management confidence, with underlying EPS growth projected at 14% annually after adjusting for IPR&D and milestone impacts.
AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting
AbbVie NYSE: ABBV told shareholders at its annual meeting that 2025 was “another excellent year” for the company, citing record sales, stronger-than-expected revenue and continued investment in its drug pipeline and business development.
6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash
Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck.
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
AbbVie ABBV stock has risen around 5% since it announced robust first-quarter 2026 results on April 29. It beat estimates for both earnings and sales and the guidance for 2026 revenues and earnings was also raised.
10 Years, Zero Regrets: The Dividend Stocks I Keep Buying
Dividend stocks can be a pillar for long-term investing, generating passive income and offering stability even during tough environments.
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat
Earnings season is in full swing, and on April 29, three Big Pharma mainstays reported Q1 2026 earnings. Investors were looking for strong results—and strong guidance—that could serve as a sorely needed tailwind for the healthcare sector.
AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried
AbbVie delivered a strong earnings beat this week, driven by its immunology portfolio. WSJ's David Wainer explains why Wall Street is still jittery.
AbbVie: Balancing Potential Acquisition Impact With Positive Q1 2026 Earnings
AbbVie's price might have been sluggish in 2026 so far, but can the latest results change anything? Yes and no. No, because there's acquisition talk doing the rounds, which can be an earnings drag for now, even though it can be positive for revenues. Yes, because the latest results for Q1 2026 are good, with double-digit percent revenue growth and a healthy adjusted EPS rise too. The market multiples also look improved.
Price Prediction: Why AbbVie's Post-Humira Pivot Makes It a Strong Buy
Our AbbVie (NYSE:ABBV | ABBV Price Prediction) call lands on the constructive side of the ledger after a noisy but encouraging Q1 earnings report.
AbbVie Inc. (ABBV) Q1 2026 Earnings Call Transcript
AbbVie Inc. (ABBV) Q1 2026 Earnings Call Transcript
